To substantiate these results in vivo, we established a syngeneic mouse model, wherein immune resistant B16F10 melanoma cells were implanted into mice....The impact of in silico derived biomarkers on the TME and response to ICIs was then assessed using in vitro assays and an in vivo mouse model study…. The impact of in silico derived biomarkers on the TME and response to ICIs was then assessed using in vitro assays and an in vivo mouse model study...mice bearing mutant SF3B1 tumors showed improved TME and immune profiles suitable for immunotherapy, which were characterized by accumulation of CD4 and CD8 T cells, activated dendritic cells, and concomitant induction of immune effectors.